Mandate

Vinge advises Litorina in connection with acquisition of Fresks

January 15, 2016

Vinge has advised Litorina IV in connection with the acquisition of a majority shareholding in Fresks, a leading Swedish building materials and DIY chain in northern Sweden, which focuses on construction industry participants and has a turnover of SEK 875 million.

The Oscarson family and the company’s former CEO will retain a significant shareholding together with Litorina and other key personnel within the company’s management.

Vinge’s team consisted of partners Johan Winnerblad and Louise Brorsson Salomon together with, among others, associates Charlotta Järnstedt, Helena Håkansson, Emil Fahlén Godö, Jasmin Draszka-Ali and Anne Wijkman. 

Related

Vinge advises Aspo on its acquisition of Swed Handling

Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024